EQS-Adhoc: BayWa AG: Impairment tests lead to extraordinary depreciation of € 222.2 million (impairment tests in accordance with IAS 36)

EQS-Ad-hoc: BayWa AG / Key word(s): Half Year Report BayWa AG: Impairment tests lead to extraordinary depreciation of € 222.2 million (impairment tests in accordance with IAS 36) 27-Sep-2024 / 12:48 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The impairment tests that became necessary led to non-cash impairment losses of € 222.2 million, which were recognised as depreciation in the Half-Year Financial Statements 2024. At € 171.5 million, the largest share was attributable to BayWa r.e. AG, a 51% subsidiary of BayWa AG. These depreciations have no negative impact on the BayWa Group’s ongoing restructuring efforts and the implementation of the restructuring concept currently being developed. The full Half-Year Financial Statements 2024 will be published today on the BayWa Group website. Contact: Josko Radeljic, BayWa AG, Head of Investor Relations, tel. [phone], Fax [phone], e-mail: [e-mail]   End of Inside Information 27-Sep-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com

Language:	English
Company:	BayWa AG
	Arabellastraße 4
	81925 Munich
	Germany
Phone:	+49 (0)89/ 9222-3691
Fax:	+49 (0)89/ 9212-3680
E-mail:	[e-mail]
Internet:	www.baywa.com
ISIN:	DE0005194062, DE0005194005,
WKN:	519406, 519400,
Listed:	Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Stuttgart, Tradegate Exchange
EQS News ID:	1997511

End of Announcement	EQS News Service

1997511  27-Sep-2024 CET/CEST